Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension

Randomized Control Clinical Trial for Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02211352

Acronym

KRGCBP

Enrollment

Registered

2014-08-07

Start date

2012-05-31

Completion date

2014-07-31

Last updated

2014-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

blood pressure, ginseng

Brief summary

The purpose of this study is to determine Korean red ginseng (KRG)treatment could decrease central blood pressure in subjects with hypertension.

Detailed description

Participants with hypertension who were treated with antihypertensive agents were randomly assigned to an active (KRG 2 g/day) or a placebo treatment group in a double-blind cross over manner. Participants were not allowed to change their antihypertensive medications except safety issue. Brachial systolic BP (SBP), diastolic BP (DBP), Central SBP and DBP will measured at baseline,at 2 and 4 months. Efficacy and safety data will be monitored by Daegu Catholic University Medical Center Institutional Review Board and reported to the Korean Ginseng Society.

Interventions

DRUGKorean Red Ginseng Capsules

Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week

DRUGPlacebo

Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Essential hypertension * diastolic blood pressure 100 mmHg or less and systolic blood pressure 160 mmHg or less

Exclusion criteria

* Secondary hypertension * Serum creatinin above 1.5 mg/dL * aspartate aminotransferase(AST) and alanine aminotransferaseALT above two times upper normal limits * Uncontrolled diabetes (Hb A1c \< 9%) * Acute myocardial infarction or coronary artery disease intervention within six months * Moderate to severe congestive heart failure * HIV positive * Immunocompromized host * Allergy to Korean red ginseng * Pregnancy or plan to pregnancy * Alcohol or drug abuse * Attend to other clinical trial within 12 weeks

Design outcomes

Primary

Measure	Time frame
central blood pressure change after treatment of Korea Red Ginseng	baseline, 8 weeks and 16 weeks after treatment

Secondary

Measure	Time frame
brachial systolic and diastolic blood pressure	baseline, 8 week, 16 week.
Augumentation index	baseline, 8 week, 16 week.
ESR(erythrocyte sedmentation rate)	baseline, 8 week, 16 week.
CRP(C-reactive protein)	baseline, 8 week, 16 week.

Other

Measure	Time frame
Number of participants with adverse events	baseline, 8 week, 16 week
fasting blood glucose	baseline, 8 week, 16 week
Hb A1c(Hemoglobin A1c)	baseline, 8 week, 16 week
AST(Aspartate Aminotransferase)	baseline, 8 week, 16 week

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026